Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.757
Journals
Biomedicines
Special Issues
Treatment for Pulmonary Fibrosis, Volume II
share announcement

Special Issue "Treatment for Pulmonary Fibrosis, Volume II"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 May 2023 | Viewed by 1677

Special Issue Editors

Prof. Dr. Hiroshi Mukae

E-Mail Website
Guest Editor
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Interests: Interstitial pneumonia; pulmonary infection
Special Issues, Collections and Topics in MDPI journals
Dr. Noriho Sakamoto

E-Mail Website
Guest Editor
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Interests: sarcoidosis; interstitial lung disease; bronchoalveolar lavage; lymphangioleiomyomatosis; lung

Special Issue Information

Dear Colleagues,

Pulmonary fibrosis is characterized by the excessive deposition of extracellular matrices and destruction of the pulmonary parenchyma. The cause or contributing factor of pulmonary fibrosis is often unknown, and some diseases, including idiopathic pulmonary fibrosis, have poor prognosis despite treatment. Recently, progressive fibrosing interstitial lung disease (PF-ILD) or progressive pulmonary fibrosis (PPF) has been advocated to this phenotype, but there are many uncertainties and problems left to be resolved in the term “PF-ILD or PPF”.

This Special Issue, “Pulmonary Fibrosis: From Pathogenesis to Therapeutics”, aims to focus on novel approaches to the pathogenesis, diagnosis and therapeutics of pulmonary fibrosis at basic to clinical levels.

Prof. Dr. Hiroshi Mukae
Dr. Noriho Sakamoto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • idiopathic pulmonary fibrosis
  • anti-fibrotic drug
  • progressive fibrosing interstitial lung disease
  • mechanism
  • pathophysiology
  • interstitial lung disease
  • biomarker

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

get_app
Article
Two-Pore-Domain Potassium Channel TREK–1 Mediates Pulmonary Fibrosis through Macrophage M2 Polarization and by Direct Promotion of Fibroblast Differentiation
by
Yunna Zhang
,
Jiafeng Fu
,
Yang Han
,
Dandan Feng
,
Shaojie Yue
,
Yan Zhou
and
Ziqiang Luo
Biomedicines 2023, 11(5), 1279; https://doi.org/10.3390/biomedicines11051279 - 26 Apr 2023
Viewed by 721
Abstract
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by myofibroblast proliferation and abnormal accumulation of extracellular matrix in the lungs. After lung injury, M2 macrophages mediate the pathogenesis of pulmonary fibrosis by secreting fibrotic cytokines that promote myofibroblast activation. The TWIK-related potassium [...] Read more.
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by myofibroblast proliferation and abnormal accumulation of extracellular matrix in the lungs. After lung injury, M2 macrophages mediate the pathogenesis of pulmonary fibrosis by secreting fibrotic cytokines that promote myofibroblast activation. The TWIK-related potassium channel (TREK–1, also known as KCNK2) is a K2P channel that is highly expressed in cardiac, lung, and other tissues; it worsens various tumors, such as ovarian cancer and prostate cancer, and mediates cardiac fibrosis. However, the role of TREK–1 in lung fibrosis remains unclear. This study aimed to examine the effects of TREK–1 on bleomycin (BLM)-induced lung fibrosis. The results show that TREK–1 knockdown, mediated by the adenovirus or pharmacological inhibition of TREK–1 with fluoxetine, resulted in diminished BLM-induced lung fibrosis. TREK–1 overexpression in macrophages remarkably increased the M2 phenotype, resulting in fibroblast activation. Furthermore, TREK–1 knockdown and fluoxetine administration directly reduced the differentiation of fibroblasts to myofibroblasts by inhibiting the focal adhesion kinase (FAK)/p38 mitogen-activated protein kinases (p38)/Yes-associated protein (YAP) signaling pathway. In conclusion, TREK–1 plays a central role in the pathogenesis of BLM-induced lung fibrosis, which serves as a theoretical basis for the inhibition of TREK–1 as a potential therapy protocol for lung fibrosis. Full article
(This article belongs to the Special Issue Treatment for Pulmonary Fibrosis, Volume II)
►▼ Show Figures

Figure 1

Review

Jump to: Research

get_app
Review
Epigenetics Approaches toward Precision Medicine for Idiopathic Pulmonary Fibrosis: Focus on DNA Methylation
by
Wiwin Is Effendi
and
Tatsuya Nagano
Biomedicines 2023, 11(4), 1047; https://doi.org/10.3390/biomedicines11041047 - 28 Mar 2023
Cited by 1 | Viewed by 749
Abstract
Genetic information is not transmitted solely by DNA but by the epigenetics process. Epigenetics describes molecular missing link pathways that could bridge the gap between the genetic background and environmental risk factors that contribute to the pathogenesis of pulmonary fibrosis. Specific epigenetic patterns, [...] Read more.
Genetic information is not transmitted solely by DNA but by the epigenetics process. Epigenetics describes molecular missing link pathways that could bridge the gap between the genetic background and environmental risk factors that contribute to the pathogenesis of pulmonary fibrosis. Specific epigenetic patterns, especially DNA methylation, histone modifications, long non-coding, and microRNA (miRNAs), affect the endophenotypes underlying the development of idiopathic pulmonary fibrosis (IPF). Among all the epigenetic marks, DNA methylation modifications have been the most widely studied in IPF. This review summarizes the current knowledge concerning DNA methylation changes in pulmonary fibrosis and demonstrates a promising novel epigenetics-based precision medicine. Full article
(This article belongs to the Special Issue Treatment for Pulmonary Fibrosis, Volume II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop